Abdallah Simaika, MD in Applegate, MI - Medicare Orthopaedic Surgery

Abdallah Simaika, MD is a medicare enrolled "Orthopaedic Surgery - Sports Medicine" physician in Applegate, Michigan. His current practice location is 2797 Applegate Rd, Po Box 55, Applegate, Michigan. You can reach out to his office (for appointments etc.) via phone at (810) 705-1964.

Abdallah Simaika is licensed to practice in Michigan (license number 4301044184) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1598878266.

Contact Information

	Abdallah Simaika, MD
	2797 Applegate Rd, Po Box 55, Applegate, MI 48401-9752
	(810) 705-1964
	Not Available

Physician's Profile

Full Name	Abdallah Simaika
Gender	Male
Speciality	Orthopaedic Surgery - Sports Medicine
Location	2797 Applegate Rd, Applegate, Michigan
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1598878266
Provider Enumeration Date: 08/16/2006
Last Update Date: 11/10/2017

Medicare PECOS Information:

PECOS PAC ID: 3870594138
Enrollment ID: I20171129002222

Medical Identifiers

Medical identifiers for Abdallah Simaika such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1598878266	NPI	-	NPPES
439162710	Medicaid	IL

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207XX0005X	Orthopaedic Surgery - Sports Medicine	4301044184 (Michigan)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Abdallah Simaika is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Abdallah Simaika, MD 50 Dr Warren Tuttle Drive, Harrisburg, IL 62946 Ph: (618) 253-7671	Abdallah Simaika, MD 2797 Applegate Rd, Po Box 55, Applegate, MI 48401-9752 Ph: (810) 705-1964

News Archive

New strategies to improve developing countries' access to low-cost generic drugs needed, experts say

New strategies that ensure developing countries have access to low-cost generic medicines and encourage innovation are needed, according to experts who attended a recent meeting sponsored by the WHO, World Intellectual Property Organization, and World Trade Organization (WTO) that addressed growing concern that strict intellectual property protections are limiting access to low-cost generic medicines, BMJ News reports.

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

Living sensor can warn of arsenic pollution

Scientists studying arsenic pollution have discovered a living sensor that can spot contamination. They have also discovered new bacteria that can clean up arsenic spills even in previously untreatable cold areas, microbiologists heard today (Monday 8 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

Abdallah Simaika, MD - Medicare Orthopaedic Surgery in Applegate, MI